A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
Tóm tắt
In the USA, psoriasis affects approximately 3% of the population and costs more than $110 billion annually. The development of targeted biologics has revolutionized psoriasis management, but at an increasing cost. According to Joint AAD/NPF guidelines, an important need exists to identify biomarkers that can predict the appropriate biologic agent for patients. A survey of community dermatologists was developed to address (1) significant factors influencing biologic therapy utilization in psoriasis; (2) the clinical utility of a test stratifying biologic response. Respondents confirmed that trial and error leads to frequent biologic switching. The survey indicated that 82% of dermatologists switch 10–30% of their patients in the first year and 98% switch intra-class for at least 50% of non-responding patients. The trial and error is due, in part, to formularies influencing the physician 77% of the time, with only 14% reporting that their first choice and the formulary alignment is greater than 75%. Compounding trial and error, 93% of the physicians report that they wait at least 12 weeks before determining non-response, in alignment with AAD/NPF guidelines. The lack of precision medicine and this trial-and-error approach result in unnecessary wasted spending and suboptimal patient outcomes. After being given an overview of Mind.Px, a dermal biomarker patch used to predict therapeutic response to a biologic class, survey participants expressed that:
Surveyed dermatologists believe a test that predicts psoriasis treatment response to a class of biologic drugs would lessen trial and error, provide a tool for physicians to make more informed decisions about drug selection, improve patient outcomes, and significantly reduce wasted spending.
Tài liệu tham khảo
Malatestinic W, Amato D, Feldman SR. Formulary decisions and the evolution of psoriasis treatment. J Clin Pathways. 2015;1:43–7.
Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–8.
Trettin B, Feldman SR, Andersen F, Danbjørg DB, Agerskov H. A changed life: the life experiences of patients with psoriasis receiving biological treatment. Br J Dermatol. 2020;183(3):516–23.
Strohal R, Prinz JC, Girolomoni G, Nast A. A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus. J Eur Acad Dermatol Venereol. 2015;29(12):2390–8.
Glasure S. BioSpace. BioSpace feature: a look at miracle drug Humira’s journey to proven efficacy. 2018. https://www.biospace.com/article/biospace-feature-a-look-at-miracle-drug-humira-s-journey-to-proven-efficacy-/. Accessed Mar 12, 2021.
AbbVie. Humira. Access for your patients. https://www.humiradermpro.com/humira-formulary-coverage. Accessed Mar 12, 2021.
Wu JJ, Feldman SR, Rastogi S, Menges B, Linghohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29(8):769–74.
Stoll D, Gutschmidt D, Dulitz S. New paths in predictive payer coverage. PolicyReporter™. http://policyreporter.com. Accessed Mar 12, 2021.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient. Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.
Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
de Carvalho AVE, Duquia RP, Horta BL, Bonamigo RR. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2017;17(1):29–51.
Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl M. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–5.